NeuroSense Therapeutics (NASDAQ:NRSN) Posts Earnings Results

NeuroSense Therapeutics (NASDAQ:NRSN) posted its quarterly earnings results on Wednesday. The company reported ($0.11) earnings per share (EPS) for the quarter, Zacks reports.

NeuroSense Therapeutics Trading Up 3.2 %

Shares of NRSN stock traded up $0.04 on Wednesday, hitting $1.13. The stock had a trading volume of 401,737 shares, compared to its average volume of 264,754. NeuroSense Therapeutics has a twelve month low of $0.51 and a twelve month high of $2.33. The company has a fifty day moving average price of $1.12 and a two-hundred day moving average price of $1.03. The firm has a market cap of $15.38 million, a P/E ratio of -1.27 and a beta of 1.38.

Wall Street Analyst Weigh In

Separately, Maxim Group reiterated a “hold” rating on shares of NeuroSense Therapeutics in a research report on Monday.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.